An ideal material for repair of congenitally malformed hearts would encourage tissue regeneration with growth potential. Decellularized porcine small intestinal submucosa extracellular matrix (SIS-ECM) promotes tissue regeneration in animal models and noncardiac human applications. This retrospective review evaluates SIS-ECM for reconstruction of congenital heart defects. From June 2007 to May 2009, SIS-ECM patches were used in 43 operations on 40 patients aged 2 days to 13 years. In 16 cases, the SIS-ECM was used for pericardial closure. The SIS-ECM was used for cardiac or great vessel repair in 37 cases: atrial septal defect repair in 11, pulmonary arterioplasty in 10, right ventricular outflow tract patch in 6, pulmonary monocusp valve creation in 5, superior vena cava patch in 2 and aortoplasty in 2, valve leaflet augmentation in 2, and repair of unroofed coronary sinus in 1. Follow-up was complete. There were 5 deaths, all unrelated to the SIS-ECM. Mean follow-up was 7.85 months (0.5-24 months). No pericardial effusions or intracardiac or intravascular thromboses occurred related to the SIS-ECM. The patches did not shrink or calcify. Four of 5 monocusp valves were competent and none were stenotic. One patient who underwent tricuspid valve anterior leaflet augmentation with SIS-ECM required tricuspid valve replacement 4 months later for severe regurgitation following a catheter-based procedure. Explanted tissue showed resorption of the SIS-ECM, replacement with organized collagen, and re-endothelialization. Repair of congenital heart defects using SIS-ECM is feasible and safe. In valve reconstruction, this procedure shows potential for replacement by autologous tissue. Longer-term follow-up is required to assess the potential for growth.
10 December 2021 in The Annals of Thoracic Surgery
The utility of implanting a bioscaffold mitral valve consisting of porcine small intestinal submucosa (PSIS) in a juvenile baboon model (12 to 14 months old at the time of implant; n = 3) to assess their in vivo tissue remodeling responses was investigated. Our findings demonstrated that the PSIS mitral valve exhibited the robust presence of de novo extracellular matrix (ECM) at all explantation time points (at 3-, 11-, and 20-months). Apart from a significantly lower level of proteoglycans in the implanted valve’s annulus region (p < 0.05) at 3 months compared to the 11- and 20-month explants, there were no other significant differences (p > 0.05) found between any of the other principal valve ECM components (collagen and elastin) at the leaflet, annulus, or chordae tendinea locations, across these time points. In particular, neochordae tissue had formed, which seamlessly integrated with the native papillary muscles. However, additional processing will be required to trigger accelerated, uniform and complete valve ECM formation in the recipient. Regardless of the specific processing done to the bioscaffold valve, in this proof-of-concept study, we estimate that a 3-month window following bioscaffold valve replacement is the timeline in which complete regeneration of the valve and integration with the host needs to occur.
The Rastelli operation is accepted as 1 of the standard techniques for complete transposition of the great arteries (TGA) and TGA-type double-outlet right ventricle with left ventricular outflow tract (LVOT) obstruction. The half-turned truncal switch (HTTS) operation has been reported as an alternative to the Rastelli approach. The aim of this study was to compare these 2 operations for children with TGA and LVOT obstruction (TGA/LVOTO). Between 2012 and 2024, 11 patients underwent TGA/LVOTO repair. The median age at repair was 12 months and median weight was 8.4 kg. Preoperative baseline and follow-up data were collected from records. Diagnosis was TGA with pulmonary stenosis in 7 cases, TGA-type double-outlet right ventricle in 4 cases. One patient had a hypoplastic right ventricle. Rastelli operation was performed in 6 patients, and 5 patients underwent the HTTS operation. The right ventricular outflow tract was augmented using a CorMatrix monocusp valve patch in 4 patients during HTTS operation, and Contegra (Medtronic) (n = 5) or pulmonary homograft (n = 1) valve during Rastelli operation. There were no early deaths; all patients survived the procedure. The groups did not differ significantly in gender, age/weight/height in complete repair, previous surgical or transcatheter procedures, postoperative length of stay, genetic/syndromic abnormalities, and crossclamp time during complete repair. The mean cardiopulmonary bypass time was significantly longer for patients after HTTS (HTTS, 264 ± 24 minutes vs Rastelli, 174 ± 57 minutes; P = .01). The mean follow-up time was 5.2 ± 4.8 years (range, 1 month to 12 years). There was no significant difference between groups in follow-up time, pulmonary stenosis gradient, or degree of pulmonary or aortic insufficiency. Conduit reintervention was required in 4 patients from the Rastelli group and none in the HTTS group (Rastelli, 67% vs HTTS, 0%; P = .06). Our study suggests that in children with TGA or TGA-type double-outlet right ventricle with LVOT obstruction, the half-turned truncal switch operation provides an unobstructed LVOT, results in less need for reintervention, and shows no disadvantage associated with right ventricular outflow tract growth at any anatomic level. Further investigation on this topic is needed.